NDAORALTABLET
Approved
Dec 1959
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
NATURETIN-5 (bendroflumethiazide) by Bristol Myers Squibb is clinical pharmacology nadolol nadolol is a nonselective beta-adrenergic receptor blocking agent. Approved for hypertension, to lower blood pressure. First approved in 1959.
Drug data last refreshed 8h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NATURETIN-5 (bendroflumethiazide) is a thiazide diuretic approved in 1959 for hypertension management. It lowers blood pressure by reducing sodium reabsorption in the distal renal tubule, decreasing extracellular fluid volume and peripheral vascular resistance. The product is indicated for hypertension and acts via diuretic and natriuretic mechanisms.
LOE Approaching
As an LOE-approaching product with no recent investment data, the brand team is likely small and focused on maintaining legacy market share rather than growth initiatives.
Mechanism of Action
CLINICAL PHARMACOLOGY Nadolol Nadolol is a nonselective beta-adrenergic receptor blocking agent. Clinical pharmacology studies have demonstrated beta-blocking activity by showing (1) reduction in heart rate and cardiac output at rest and on exercise, (2) reduction of systolic and diastolic blood…
Worked on NATURETIN-5 at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.